Category: pharma

Health Policies in India and its Implementation

Introduction Following the pandemic India, a developing nation with limited resources, has created a number of policies to expand its healthcare system. The government has not only changed existing policies to better suit the times, but it has also boldly introduced new ones. The article’s goal is to discuss some policies with their goals and … Continue reading Health Policies in India and its Implementation

Read more »

Medical Device Registration Process In India: A Primer

In the preceding five years, the medical device industry in India has undergone significant changes, particularly on the regulatory front. Still at a transitory phase, the medical device industry To begin with, the Medical Devices Rules, 2017 (“MDR”), were enacted to regulate and standardise medical devices in India, among other things. The rules came into … Continue reading Medical Device Registration Process In India: A Primer

Read more »

Note on CCI’s Report on the Pharmaceutical Sector

Key findings and observations from a market analysis conducted by the Competition Commission of India (CCI) were revealed on November 18, 2021. There are many components of the study, including trade margins, disputes between online and offline distributors, trade associations, and modes of distribution, that are examined. To date, there have been 43 complaints about … Continue reading Note on CCI’s Report on the Pharmaceutical Sector

Read more »

Enantiomer Patents: Non Obviousness In Secondary Pharmaceutical Patents

Enantiomers, Racemate & Chirality ‘Stereochemistry’ is the study of spatial arrangements of atoms in a molecule. A molecule may be similar in chemical makeup to another molecule, however, the spatial arrangements of atoms in these may differ. Molecules so related are called stereoisomers. Enantiomers exist as subsets of these stereoisomers, where, the spatial arrangement of … Continue reading Enantiomer Patents: Non Obviousness In Secondary Pharmaceutical Patents

Read more »

Highlights of National Commission for Indian System of Medicines Bill, (need for preserving, regulating, organizing the Age Old Medicine Systems)

Introduction As a child growing up in India, or even as an adult, each one of us has had a fair experience of how grandmothers in Indian households peculiarly happen to have herbal prescriptions for all the ailments that could come our way, famously known as ‘Daadi ke nuskhe’ and we have to agree, most … Continue reading Highlights of National Commission for Indian System of Medicines Bill, (need for preserving, regulating, organizing the Age Old Medicine Systems)

Read more »

E- Pharmacy In India (Ban Or No Ban)

‘E-pharmacies’ are in quandary after the decisions taken by country’s two High Court’s over the issue of online sale of medicines. The Hon’ble Delhi High Court deferred the hearing on the matter and extended its interim stay on the online sale of medicines through e-pharmacies. However, the Hon’ble Madras High Court temporarily suspended the ban … Continue reading E- Pharmacy In India (Ban Or No Ban)

Read more »

Injunction against Cipla COPD Drug ‘INDAFLO’ Upheld: Delhi High Court

Reportedly, on an appeal filed by Cipla pertaining to COPD drug INDAFLO, the Delhi High court division bench maintained the interim injunction imposed by single judge against Cipla.  As per the order, Cipla has now been restrained from, inter alia, using, manufacturing, importing, selling any pharmaceutical products etc. containing ‘INDACATEROL‘ or ‘INDACATEROL Maleate‘, alone or … Continue reading Injunction against Cipla COPD Drug ‘INDAFLO’ Upheld: Delhi High Court

Read more »

Analysis of the rejection of Lumacaftor (Polymorph) patent application in India

We have been receiving requests from our Pharma clients/readers of the blog for the analysis of the decision/ facts that led to rejection of Lumacaftor (Polymorph) patent application in India since last year. Here is our take: Details of the Patent Application and important dates: Patent application number in India 2056/KOLNP/2010 Title of the invention … Continue reading Analysis of the rejection of Lumacaftor (Polymorph) patent application in India

Read more »

Merk’s patent valid but Teva’s Nasonex generic non-infringing

In Merck Sharp & Dohme Corp.  (hereinafter referred to be as “Merck”) v. Teva Pharms. United States, Inc. (hereinafter referred to be as “Teva”) decided on November 16, 2016, Teva’s application of Abbreviated New Drug Application (hereinafter referred to as “ANDA”) no. 205149 had triggered Merck to file infringement suit against Teva in respect of … Continue reading Merk’s patent valid but Teva’s Nasonex generic non-infringing

Read more »

Combating Opioid Misuse – COMBAT (Curb Opioid Misuse By Advancing Technology Act of 2016)

The Congress recently introduced a bill on the COMBAT Act (Curb Opioid Misuse By Advancing Technology Act of 2016) to incentivize the development of abuse-deterrent opioids by amending the Federal Food, Drug, and Cosmetic Act to extend the exclusivity period for certain drug products developed or labeled so as to reduce drug abuse, and for … Continue reading Combating Opioid Misuse – COMBAT (Curb Opioid Misuse By Advancing Technology Act of 2016)

Read more »

Categories

Archives

  • March 2024
  • February 2024
  • January 2024
  • December 2023
  • November 2023
  • October 2023
  • September 2023
  • August 2023
  • July 2023
  • June 2023
  • May 2023
  • April 2023
  • March 2023
  • February 2023
  • January 2023
  • December 2022
  • November 2022
  • October 2022
  • September 2022
  • August 2022
  • July 2022
  • June 2022
  • May 2022
  • April 2022
  • March 2022
  • February 2022
  • January 2022
  • December 2021
  • November 2021
  • October 2021
  • September 2021
  • August 2021
  • July 2021
  • June 2021
  • May 2021
  • April 2021
  • March 2021
  • February 2021
  • January 2021
  • December 2020
  • November 2020
  • October 2020
  • September 2020
  • August 2020
  • July 2020
  • June 2020
  • May 2020
  • April 2020
  • March 2020
  • February 2020
  • January 2020
  • December 2019
  • November 2019
  • October 2019
  • September 2019
  • August 2019
  • July 2019
  • June 2019
  • May 2019
  • April 2019
  • March 2019
  • February 2019
  • January 2019
  • December 2018
  • November 2018
  • October 2018
  • September 2018
  • August 2018
  • July 2018
  • June 2018
  • May 2018
  • April 2018
  • March 2018
  • February 2018
  • January 2018
  • December 2017
  • November 2017
  • September 2017
  • August 2017
  • July 2017
  • June 2017
  • May 2017
  • April 2017
  • March 2017
  • February 2017
  • January 2017
  • December 2016
  • November 2016
  • October 2016
  • September 2016
  • August 2016
  • July 2016
  • June 2016
  • May 2016
  • April 2016
  • March 2016
  • February 2016
  • January 2016
  • December 2015
  • November 2015
  • October 2015
  • September 2015
  • August 2015
  • July 2015
  • June 2015
  • May 2015
  • April 2015
  • March 2015
  • February 2015
  • January 2015
  • December 2014
  • November 2014
  • October 2014
  • September 2014
  • August 2014
  • July 2014
  • June 2014
  • May 2014
  • April 2014
  • March 2014
  • February 2014
  • January 2014
  • December 2013
  • November 2013
  • October 2013
  • September 2013
  • August 2013
  • July 2013
  • June 2013
  • May 2013
  • April 2013
  • March 2013
  • February 2013
  • January 2013
  • December 2012
  • November 2012
  • September 2012
  • August 2012
  • July 2012
  • June 2012
  • May 2012
  • April 2012
  • March 2012
  • February 2012
  • January 2012
  • December 2011
  • November 2011
  • October 2011
  • September 2011
  • August 2011
  • July 2011
  • June 2011
  • May 2011
  • April 2011
  • March 2011
  • February 2011
  • January 2011
  • December 2010
  • September 2010
  • July 2010
  • June 2010
  • May 2010
  • April 2010